Short Interest in Curis, Inc. (NASDAQ:CRIS) Declines By 48.1%

Curis, Inc. (NASDAQ:CRIS) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 168,213 shares, a decrease of 48.1% from the August 15th total of 324,276 shares. Based on an average daily trading volume, of 177,225 shares, the days-to-cover ratio is currently 0.9 days. Currently, 8.5% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Zacks Research raised shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 9th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. HC Wainwright reiterated a “buy” rating on shares of Curis in a report on Monday, August 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $43.00.

Curis Stock Performance

Curis stock traded up $0.01 during mid-day trading on Tuesday, reaching $1.13. The company’s stock had a trading volume of 156,704 shares, compared to its average volume of 123,473. The business’s 50 day simple moving average is $3.13 and its 200 day simple moving average is $8.91. The company has a market capitalization of $2.36 million, a price-to-earnings ratio of -0.08 and a beta of 3.01. Curis has a 12 month low of $1.08 and a 12 month high of $35.84.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. As a group, sell-side analysts expect that Curis will post -15.65 EPS for the current year.

Institutional Investors Weigh In On Curis

Institutional investors and hedge funds have recently modified their holdings of the company. Focused Wealth Management Inc acquired a new stake in Curis in the 2nd quarter valued at about $26,000. BlackRock Inc. acquired a new position in Curis during the second quarter worth approximately $28,000. Flputnam Investment Management Co. bought a new stake in Curis in the second quarter valued at approximately $128,000. Renaissance Technologies LLC raised its stake in Curis by 52.2% in the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 125,823 shares during the period. Finally, Cable Car Capital LP bought a new position in shares of Curis during the 2nd quarter worth approximately $696,000. 29.97% of the stock is owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.